Connection

STEPHEN YENZEN LAI to Protein Kinase Inhibitors

This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Protein Kinase Inhibitors.
Connection Strength

0.442
  1. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab. 2021 09 27; 106(10):2962-2978.
    View in: PubMed
    Score: 0.259
  2. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271.
    View in: PubMed
    Score: 0.079
  3. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014 Mar; 36(3):375-84.
    View in: PubMed
    Score: 0.036
  4. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005 Jun 23; 24(27):4442-9.
    View in: PubMed
    Score: 0.021
  5. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol. 2024; 15:1369780.
    View in: PubMed
    Score: 0.019
  6. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer. 2022 11 01; 29(11):R173-R190.
    View in: PubMed
    Score: 0.017
  7. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 2013 Aug 27; 11:198.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.